Logo image of IDXX

IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis

USA - NASDAQ:IDXX - US45168D1046 - Common Stock

634.36 USD
-13.04 (-2.01%)
Last: 10/28/2025, 8:00:24 PM
634.36 USD
0 (0%)
After Hours: 10/28/2025, 8:00:24 PM
Fundamental Rating

7

IDXX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX is not valued too expensively and it also shows a decent growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
Each year in the past 5 years IDXX has been profitable.
Each year in the past 5 years IDXX had a positive operating cash flow.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

IDXX has a better Return On Assets (29.59%) than 98.94% of its industry peers.
IDXX's Return On Equity of 67.56% is amongst the best of the industry. IDXX outperforms 99.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 37.30%, IDXX belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
IDXX had an Average Return On Invested Capital over the past 3 years of 35.08%. This is significantly above the industry average of 9.01%.
The last Return On Invested Capital (37.30%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 29.59%
ROE 67.56%
ROIC 37.3%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

Looking at the Profit Margin, with a value of 24.41%, IDXX belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.09%, IDXX belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
IDXX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 61.54%, IDXX is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
IDXX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.09%
PM (TTM) 24.41%
GM 61.54%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

IDXX has an Altman-Z score of 21.57. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IDXX (21.57) is better than 95.24% of its industry peers.
The Debt to FCF ratio of IDXX is 1.43, which is an excellent value as it means it would take IDXX, only 1.43 years of fcf income to pay off all of its debts.
IDXX's Debt to FCF ratio of 1.43 is amongst the best of the industry. IDXX outperforms 89.95% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that IDXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.71, IDXX is not doing good in the industry: 70.37% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 1.43
Altman-Z 21.57
ROIC/WACC4.14
WACC9.02%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.11 indicates that IDXX should not have too much problems paying its short term obligations.
IDXX's Current ratio of 1.11 is on the low side compared to the rest of the industry. IDXX is outperformed by 85.71% of its industry peers.
IDXX has a Quick Ratio of 1.11. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
IDXX has a Quick ratio of 0.79. This is amonst the worse of the industry: IDXX underperforms 84.66% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.79
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.45% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
IDXX shows a small growth in Revenue. In the last year, the Revenue has grown by 6.68%.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)12.45%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%20.2%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%10.55%

3.2 Future

Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.68% on average per year.
The Revenue is expected to grow by 8.69% on average over the next years. This is quite good.
EPS Next Y14.37%
EPS Next 2Y13.27%
EPS Next 3Y13.08%
EPS Next 5Y11.68%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15 20

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 52.82, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.25% of the companies listed in the same industry.
IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 43.95, the valuation of IDXX can be described as expensive.
Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than 70.37% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, IDXX is valued quite expensively.
Industry RankSector Rank
PE 52.82
Fwd PE 43.95
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 69.84% of the companies in the same industry.
73.02% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 65.54
EV/EBITDA 37.44
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
IDXX's earnings are expected to grow with 13.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.68
PEG (5Y)2.91
EPS Next 2Y13.27%
EPS Next 3Y13.08%

0

5. Dividend

5.1 Amount

IDXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IDEXX LABORATORIES INC

NASDAQ:IDXX (10/28/2025, 8:00:24 PM)

After market: 634.36 0 (0%)

634.36

-13.04 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners97.04%
Inst Owner Change-0.21%
Ins Owners0.2%
Ins Owner Change2.22%
Market Cap50.75B
Revenue(TTM)4.04B
Net Income(TTM)985.66M
Analysts79.05
Price Target694.47 (9.48%)
Short Float %2.24%
Short Ratio4.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.76%
Min EPS beat(2)1.72%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)4.73%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.6%
EPS beat(12)12
Avg EPS beat(12)4.41%
EPS beat(16)14
Avg EPS beat(16)3.9%
Revenue beat(2)1
Avg Revenue beat(2)-0.02%
Min Revenue beat(2)-1.92%
Max Revenue beat(2)1.88%
Revenue beat(4)2
Avg Revenue beat(4)-0.58%
Min Revenue beat(4)-2.33%
Max Revenue beat(4)1.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.32%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0.43%
PT rev (3m)28.15%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)1.03%
EPS NY rev (1m)0.13%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)2.2%
Valuation
Industry RankSector Rank
PE 52.82
Fwd PE 43.95
P/S 12.57
P/FCF 65.54
P/OCF 56.03
P/B 34.79
P/tB 53.95
EV/EBITDA 37.44
EPS(TTM)12.01
EY1.89%
EPS(NY)14.44
Fwd EY2.28%
FCF(TTM)9.68
FCFY1.53%
OCF(TTM)11.32
OCFY1.78%
SpS50.47
BVpS18.24
TBVpS11.76
PEG (NY)3.68
PEG (5Y)2.91
Graham Number70.2
Profitability
Industry RankSector Rank
ROA 29.59%
ROE 67.56%
ROCE 59.57%
ROIC 37.3%
ROICexc 39.73%
ROICexgc 50.01%
OM 31.09%
PM (TTM) 24.41%
GM 61.54%
FCFM 19.18%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.69%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.29%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 1.43
Debt/EBITDA 0.74
Cap/Depr 95.5%
Cap/Sales 3.26%
Interest Coverage 250
Cash Conversion 65.03%
Profit Quality 78.56%
Current Ratio 1.11
Quick Ratio 0.79
Altman-Z 21.57
F-Score7
WACC9.02%
ROIC/WACC4.14
Cap/Depr(3y)119.66%
Cap/Depr(5y)117.12%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)12.45%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%20.2%
EPS Next Y14.37%
EPS Next 2Y13.27%
EPS Next 3Y13.08%
EPS Next 5Y11.68%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%10.55%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
EBIT growth 1Y15.86%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.07%
FCF growth 1Y30.65%
FCF growth 3Y7.86%
FCF growth 5Y21.29%
OCF growth 1Y21.32%
OCF growth 3Y7.13%
OCF growth 5Y15.13%

IDEXX LABORATORIES INC / IDXX FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


Can you provide the valuation status for IDEXX LABORATORIES INC?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


Can you provide the profitability details for IDEXX LABORATORIES INC?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 52.82 and the Price/Book (PB) ratio is 34.79.


Can you provide the expected EPS growth for IDXX stock?

The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.